...
首页> 外文期刊>The Journal of Thoracic and Cardiovascular Surgery >Survival of patients with clinical stage IIIA non-small cell lung cancer after induction therapy: age, mediastinal downstaging, and extent of pulmonary resection as independent predictors.
【24h】

Survival of patients with clinical stage IIIA non-small cell lung cancer after induction therapy: age, mediastinal downstaging, and extent of pulmonary resection as independent predictors.

机译:诱导治疗后临床IIIA期非小细胞肺癌患者的生存:年龄,纵隔下移和肺切除范围是独立的预测因素。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: In clinical stage IIIA non-small cell lung cancer, the role of surgical resection, particularly pneumonectomy, after induction therapy remains controversial. Our objective was to determine factors predictive of survival after postinduction surgical resection. METHODS: We retrospectively reviewed a prospectively collected database of 136 patients who underwent surgical resection after induction chemotherapy (n = 119) or chemoradiation (n = 17) from June 1990 to January 2010. RESULTS: One hundred five lobectomies or bilobectomies and 31 pneumonectomies were performed. There was 1 perioperative death (pneumonectomy). Seventy-one patients had downstaging to N0 or N1 nodal status (52%). There were 2 complete pathologic responses. Median follow-up was 42 months (range, 0.69-136 months). Overall 5-year survival for entire cohort was 33% (36% lobectomy, 22% pneumonectomy, P = .001). Patients with pathologic downstaging to pN0 or pN1 had improved 5-year survival (45% vs 20%, P = .003). For patients with pN0 or pN1 disease, survival after lobectomy was better than after pneumonectomy (48% vs 27%, P = .011). In patients with residual N2 disease, there was no statistically significant survival difference between lobectomy and pneumonectomy (5-year survival, 21% vs 19%; P = .136). Multivariate analysis showed as independent predictors of survival age (hazard ratio, 1.05; P = .002), extent of resection (hazard ratio, 2.01; P = .026), and presence of residual pN2 (hazard ratio, 1.60; P = .047). CONCLUSIONS: After induction therapy for patients with clinical stage IIIA disease, both pneumonectomy and lobectomy can be safely performed. Although survival after lobectomy is better, long-term survival can be accomplished after pneumonectomy for appropriately selected patients. Nodal downstaging is important determinant of survival, particularly after lobectomy.
机译:背景:在临床IIIA期非小细胞肺癌中,诱导治疗后手术切除(尤其是肺切除术)的作用仍存在争议。我们的目的是确定诱导后手术切除后可预测生存的因素。方法:我们回顾性收集了1990年6月至2010年1月在136例接受诱导化疗(n = 119)或化学放疗(n = 17)后接受手术切除的患者的前瞻性数据库。结果:155例肺叶切除或双肺切除和31例肺切除。执行。围手术期死亡1例(肺切除术)。七十一名患者降级为N0或N1淋巴结状态(52%)。有2个完整的病理反应。中位随访时间为42个月(范围0.69-136个月)。整个队列的总体5年生存率为33%(肺叶切除术36%,肺切除术22%,P = .001)。病理分级降至pN0或pN1的患者5年生存率有所提高(45%比20%,P = 0.003)。对于患有pN0或pN1疾病的患者,肺叶切除术后的生存期优于肺切除术后的生存期(48%比27%,P = .011)。在残留N2疾病的患者中,肺叶切除术和肺切除术之间没有统计学上显着的生存差异(5年生存率,分别为21%和19%; P = .136)。多变量分析显示生存期(危险比,1.05; P = .002),切除范围(危险比,2.01; P = .026)和是否存在残留的pN2(危险比,1.60; P =。)是独立的预测因子。 047)。结论:对IIIA期临床患者进行诱导治疗后,可以安全地进行肺切除术和肺叶切除术。尽管肺叶切除术后的生存期更好,但对于适当选择的患者,肺切除术后可以实现长期生存。淋巴结分期降低是生存的重要决定因素,尤其是在肺叶切除术后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号